We are live on !
Find out more
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$193M
AUM Growth
-$17.7M
(-8.4%)
Cap. Flow
+$7.46M
Cap. Flow % of AUM
Cap. Flow %
3.87%
Top 10 Holdings %
Top 10 Hldgs %
52.19%
Holding
80
New
22
Increased
10
Reduced
12
Closed
26
Avg Time Held
Equity + Options
0.5
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$23.6M |
| 2 |
DMK
DMK Pharmaceuticals Corporation Common Stock
DMK
|
+$9.19M |
| 3 |
Biogen
BIIB
|
+$4.6M |
| 4 |
Eagle Pharmaceuticals, Inc.
EGRX
|
+$3.86M |
| 5 |
Zimmer Biomet
ZBH
|
+$3.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$6.61M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$6.28M |
| 3 |
HCA Healthcare
HCA
|
+$5.27M |
| 4 |
Puma Biotechnology
PBYI
|
+$4.91M |
| 5 |
Philips
PHG
|
+$4.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.72% |
| 2 | Miscellaneous | 35.2% |
| 3 | Financials | 4.17% |
| 4 | Technology | 0.91% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Integer Holdings
ITGR
$4.31B
| $2.62M | 1.36% |
+51,258
| New | +$2.35M |
2017 Q3
0 quarters
|
|
27
PUT
Intuitive Surgical
ISRG
$151B
| $2.62M | 1.36% |
22,500
-60,300
| -73% | -$6.57M |
2017 Q2
1 quarter
|
|
28
Elevance Health
ELV
$92.9B
| $2.55M | 1.32% |
13,418
-349
| -3% | -$66.4K |
2017 Q2
1 quarter
|
|
29
Alnylam Pharmaceuticals
ALNY
$31B
| $2.38M | 1.23% |
+20,225
| New | +$1.73M |
2017 Q3
0 quarters
|
|
|
LMNX
30
DELISTED
Luminex Corp
LMNX
| $2.36M | 1.22% |
115,979
| – | – |
2017 Q2
1 quarter
|
|
31
Vertex Pharmaceuticals
VRTX
$127B
| $2.26M | 1.17% |
+14,874
| New | +$2.24M |
2017 Q3
0 quarters
|
|
|
32
Sanofi
SNY
$97.3B
| $2.24M | 1.16% |
45,099
-136,523
| -75% | -$6.61M |
2017 Q1
2 quarters
|
|
33
UnitedHealth
UNH
$360B
| $2.24M | 1.16% |
11,430
-9,721
| -46% | -$1.88M |
2016 Q3
4 quarters
|
|
34
Gyre Therapeutics
GYRE
$645M
| $2.13M | 1.11% |
56,218
+9,128
| +19% | +$274K |
2017 Q2
1 quarter
|
|
|
ARNA
35
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.84M | 0.95% |
72,086
+2,734
| +4% | +$62.7K |
2017 Q2
1 quarter
|
|
|
VCRA
36
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $1.76M | 0.91% |
56,106
| – | – |
2017 Q1
2 quarters
|
|
37
Evolent Health
EVH
$517M
| $1.4M | 0.73% |
+78,600
| New | +$1.62M |
2017 Q3
0 quarters
|
|
38
Madrigal Pharmaceuticals
MDGL
$10.4B
| $1.21M | 0.63% |
+26,958
| New | +$505K |
2017 Q3
0 quarters
|
|
|
AVDL
39
DELISTED
Avadel Pharmaceuticals
AVDL
| $960K | 0.5% |
91,413
| – | – |
2016 Q4
3 quarters
|
|
40
Actinium Pharmaceuticals
ATNM
$35.5M
| $915K | 0.47% |
+53,009
| New | +$1.16M |
2017 Q3
0 quarters
|
|
|
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $773K | 0.4% |
139,200
| – | – |
2017 Q2
1 quarter
|
|
42
PUT
DBV Technologies S.A. American Depositary Shares
DBVT
$569M
| $772K | 0.4% |
+1,820
| New | +$780K |
2017 Q3
0 quarters
|
|
43
Xencor
XNCR
$1.7B
| $759K | 0.39% |
+33,100
| New | +$735K |
2017 Q3
0 quarters
|
|
44
PUT
Acadia Healthcare
ACHC
$2.79B
| $659K | 0.34% |
+13,800
| New | +$673K |
2017 Q3
0 quarters
|
|
|
PGNX
45
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $652K | 0.34% |
+88,523
| New | +$562K |
2017 Q3
0 quarters
|
|
46
Spyre Therapeutics
SYRE
$7.47B
| $639K | 0.33% |
5,183
| – | – |
2016 Q2
5 quarters
|
|
47
DELISTED
Cymabay Therapeutics
CBAY
| $605K | 0.31% |
+75,000
| New | +$507K |
2017 Q3
0 quarters
|
|
|
OTIC
48
DELISTED
Otonomy, Inc.
OTIC
| $328K | 0.17% |
+100,900
| New | +$1.36M |
2017 Q3
0 quarters
|
|
|
OTIC
49
PUT
DELISTED
Otonomy, Inc.
OTIC
| $328K | 0.17% |
+100,900
| New | +$1.36M |
2017 Q3
0 quarters
|
|
|
PFNX
50
DELISTED
Pfenex Inc.
PFNX
| $259K | 0.13% |
85,867
| – | – |
2017 Q1
2 quarters
|
|
Similar funds
EFL
MAM
VV
Sio Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Sio Capital Management held 80 positions worth $193M, down 8.4% from $210M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Sio Capital Management deployed $7.46M of net new capital in Q3 2017, opening 22 new positions and adding to 10 existing holdings. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 139,862 shares worth $7.7M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Sanofi, an estimated $6.61M trimmed.
- Sio Capital Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 139,862 shares worth $7.7M.
- Sio Capital Management added most to DMK Pharmaceuticals Corporation Common Stock in Q3 2017, an estimated $9.19M increase.
- Sio Capital Management's biggest Q3 2017 reduction was Sanofi, cutting an estimated $6.61M.
- Sio Capital Management fully exited Thermo Fisher Scientific in Q3 2017, selling an estimated $6.28M.
- Sio Capital Management's ten largest holdings make up 52% of its $193M portfolio in Q3 2017.
- Sio Capital Management opened 22 new positions and closed 26 in Q3 2017.
- Sio Capital Management's portfolio value fell 8.4% quarter-over-quarter to $193M.
Based on Sio Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.